MISSISSIPPI LEGISLATURE REGULAR SESSION 2015 By: To: Public Health and Welfare Senator(s) Harkins, Collins, Hill SENATE BILL NO. 2485 (As Sent to Governor) 1 2 3 4 5 6 AN ACT ENTITLED THE "RIGHT TO TRY ACT"; TO AUTHORIZE LICENSED PHYSICIANS TO PRESCRIBE OR RECOMMEND CERTAIN INVESTIGATIONAL DRUGS, BIOLOGICAL PRODUCTS OR DEVICES TO CERTAIN ELIGIBLE TERMINALLY ILL PATIENTS; TO PROVIDE DEFINITIONS; TO AMEND SECTION 73-25-37, MISSISSIPPI CODE OF 1972, IN CONFORMITY; AND FOR RELATED PURPOSES. 7 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI: 8 SECTION 1. 9 10 This section shall be known and may be cited as the "Right to Try Act." (2) 11 12 (1) For purposes of this section: (a) "Eligible patient" means a person who meets all of the following requirements: 13 (i) 14 will lead to the person's death; 15 (ii) Has a terminal illness, or a disability that Has considered all other treatment options 16 currently approved by the United States Food and Drug 17 Administration and all relevant clinical trials conducted in this 18 state; S. B. No. 2485 15/SS02/R286SG PAGE 1 *SS02/R286SG* ~ OFFICIAL ~ G1/2 19 (iii) Has received a prescription or 20 recommendation from the person's physician for an investigational 21 drug, biological product or device; 22 (iv) Has given written informed consent, which 23 shall be at least as comprehensive as the consent used in clinical 24 trials for the use of the investigational drug, biological product 25 or device or, if the patient is a minor or lacks the mental 26 capacity to provide informed consent, a parent or legal guardian 27 has given written informed consent on the patient's behalf; and 28 (v) Has documentation from the person's physician 29 that the person has met all of the requirements of this 30 subsection. 31 (b) "Investigational drug, biological product or 32 device" means a drug, biological product or device, any of which 33 are used to treat the patient's terminal illness, that has 34 successfully completed phase one of a clinical trial but has not 35 been approved for general use by the United States Food and Drug 36 Administration and remains under investigation in a clinical 37 trial. 38 substances. The term shall not include Schedule I controlled 39 (c) "Terminal illness" means a disease that without 40 life-sustaining procedures will result in death in the near future 41 or a state of permanent unconsciousness from which recovery is 42 unlikely. S. B. No. 2485 15/SS02/R286SG PAGE 2 *SS02/R286SG* ~ OFFICIAL ~ 43 44 (d) "Written informed consent" means a written document that is: 45 (i) Signed by the: 46 1. Patient; 47 2. Parent, if the patient is a minor; 48 3. Legal guardian; or 49 4. Patient advocate designated by the patient 50 under the Uniform Health-Care Decisions Act, Section 41-41-201 et 51 seq.; and 52 53 (ii) Attested to by the patient's physician and a witness and that, at a minimum, includes all of the following: 54 1. An explanation of the currently approved 55 products and treatments for the disease or condition from which 56 the patient suffers; 57 2. An attestation that the patient concurs 58 with his or her physician in believing that all currently approved 59 and conventionally recognized treatments are unlikely to prolong 60 the patient's life; 61 3. Clear identification of the specific 62 proposed investigational drug, biological product or device that 63 the patient is seeking to use; 64 4. A description of the potentially best and 65 worst outcomes of using the investigational drug, biological 66 product or device and a realistic description of the most likely 67 outcome. The description shall include the possibility that new, S. B. No. 2485 15/SS02/R286SG PAGE 3 *SS02/R286SG* ~ OFFICIAL ~ 68 unanticipated, different, or worse symptoms might result and that 69 death could be hastened by the proposed treatment. 70 description shall be based on the physician's knowledge of the 71 proposed treatment in conjunction with an awareness of the 72 patient's condition; 73 5. The A statement that the patient's health plan 74 or third-party administrator and provider are not obligated to pay 75 for any care or treatments consequent to the use of the 76 investigational drug, biological product or device, unless they 77 are specifically required to do so by law or contract; 78 6. A statement that the patient's eligibility 79 for hospice care may be withdrawn if the patient begins curative 80 treatment with the investigational drug, biological product or 81 device and that care may be reinstated if this treatment ends and 82 the patient meets hospice eligibility requirements; and 83 7. A statement that the patient understands 84 that he or she is liable for all expenses consequent to the use of 85 the investigational drug, biological product or device and that 86 this liability extends to the patient's estate, unless a contract 87 between the patient and the manufacturer of the drug, biological 88 product or device states otherwise. 89 (3) A manufacturer of an investigational drug, biological 90 product or device may make available the manufacturer's 91 investigational drug, biological product or device to eligible 92 patients under this section. S. B. No. 2485 15/SS02/R286SG PAGE 4 This section does not require that a *SS02/R286SG* ~ OFFICIAL ~ 93 manufacturer make available an investigational drug, biological 94 product or device to an eligible patient. 95 (a) A manufacturer may: Provide an investigational drug, biological product 96 or device to an eligible patient without receiving compensation; 97 or 98 99 100 101 (b) Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product or device. (4) This section does not require a health care insurer to 102 provide coverage for the cost of any investigational drug, 103 biological product or device. 104 provide coverage for an investigational drug, biological product 105 or device. 106 (5) However, a health care insurer may This section does not require the Mississippi Department 107 of Corrections or any other governmental agency to provide 108 coverage for the cost of any investigational drug, biological 109 product or device. 110 (6) This section does not require a licensed hospital or 111 nursing home to provide new or additional services, unless 112 approved by the hospital or facility. 113 114 115 (7) This section does not require a licensed physician to offer any investigational drug, biological product or device. (8) Notwithstanding any other provision of law to the 116 contrary, no state agency or regulatory board shall revoke, fail 117 to renew, or take any other action against a physician's license S. B. No. 2485 15/SS02/R286SG PAGE 5 *SS02/R286SG* ~ OFFICIAL ~ 118 under Section 73-25-1 et seq., Mississippi Code of 1972, or 119 against a pharmacist's license under Section 73-21-71 et seq., 120 based solely on the physician's or pharmacist's recommendation to 121 an eligible patient regarding prescription for or treatment with 122 an investigational drug, biological product or device. 123 against a health care provider's Medicare certification based 124 solely on the health care provider's recommendation that a patient 125 have access to an investigational drug, biological product or 126 device is prohibited. 127 (9) Action If the clinical trial is closed due to lack of efficacy 128 or toxicity, the drug shall not be offered. 129 a drug, product or device taken by a patient outside of a clinical 130 trial, the pharmaceutical company or patient's physician shall 131 notify the patient of the information from the safety committee of 132 the clinical trial. 133 (10) If notice is given on Except in the case of gross negligence or willful 134 misconduct, any person who manufactures, imports, distributes, 135 prescribes, dispenses, compounds or administers an investigational 136 drug or device to an eligible patient with a terminal illness in 137 accordance with this section shall not be liable in any action 138 under state law for any loss, damage or injury arising out of, 139 relating to, or resulting from: 140 141 (a) The design, development, clinical testing and investigation, manufacturing, labeling, distribution, sale, S. B. No. 2485 15/SS02/R286SG PAGE 6 *SS02/R286SG* ~ OFFICIAL ~ 142 purchase, donation, dispensing, compounding, prescription, 143 administration, or use of the drug or device; or 144 145 (b) (11) The safety or effectiveness of the drug or device. If a provision of this section or its application to 146 any person or circumstance is held invalid, the invalidity does 147 not affect other provisions or applications of this section that 148 can be given effect without the invalid provision or application, 149 and to this end the provisions of this section are severable. 150 SECTION 2. Section 73-25-37, Mississippi Code of 1972, is 151 amended as follows: 152 73-25-37. (1) No duly licensed, practicing physician, 153 physician assistant, dentist, registered nurse, licensed practical 154 nurse, certified registered emergency medical technician, or any 155 other person who, in good faith and in the exercise of reasonable 156 care, renders emergency care to any injured person at the scene of 157 an emergency, or in transporting the injured person to a point 158 where medical assistance can be reasonably expected, shall be 159 liable for any civil damages to the injured person as a result of 160 any acts committed in good faith and in the exercise of reasonable 161 care or omissions in good faith and in the exercise of reasonable 162 care by such persons in rendering the emergency care to the 163 injured person. 164 (2) (a) Any person who in good faith, with or without 165 compensation, renders emergency care or treatment by the use of an 166 Automated External Defibrillator (AED) in accordance with the S. B. No. 2485 15/SS02/R286SG PAGE 7 *SS02/R286SG* ~ OFFICIAL ~ 167 provisions of Sections 41-60-31 through 41-60-35, as well as the 168 person responsible for the site where the AED is located if the 169 person has provided for compliance with the provisions of Sections 170 41-60-31 through 41-60-35, shall be immune from civil liability 171 for any personal injury as a result of that care or treatment, or 172 as a result of any act, or failure to act, in providing or 173 arranging further medical treatment, where the person acts as an 174 ordinary, reasonably prudent person would have acted under the 175 same or similar circumstances and the person's actions or failure 176 to act does not amount to willful or wanton misconduct or gross 177 negligence. 178 (b) A person who has not complied with the provisions 179 of Sections 41-60-31 through 41-60-35, but who has access to an 180 AED and uses it in good faith in an emergency as an ordinary 181 prudent person would have done in the same or similar 182 circumstances, shall be immune from civil liability for any 183 personal injury as a result of an act or omission related to the 184 operation of or failure to operate an AED if the person's actions 185 or failure to act do not amount to willful or wanton misconduct or 186 gross negligence. 187 (3) Any employee of a local public school district, a 188 private school, or parochial school, trained in the administration 189 of auto-injectable epinephrine, who provides, administers, or 190 assists in the administration of auto-injectable epinephrine, in 191 accordance with the provisions of Section 37-11-71, to a student S. B. No. 2485 15/SS02/R286SG PAGE 8 *SS02/R286SG* ~ OFFICIAL ~ 192 believed in good faith to be having an anaphylactic reaction, 193 shall be immune from civil liability for any personal injury as a 194 result of that care or treatment if the employee's actions or 195 failure to act do not amount to willful or wanton misconduct or 196 gross negligence. 197 (4) The immunity from civil liability for any personal 198 injury under subsection (2) of this section includes the licensed 199 physician who authorizes, directs or supervises the installation 200 or provision of AED equipment in or on any premises or conveyance 201 other than a medical facility, the owner of the premises where an 202 AED is used, the purchaser of the AED, a person who uses an AED 203 during an emergency for the purpose of attempting to save the life 204 of another person who is or who appears to be in cardiac arrest, 205 and the person who provides the CPR and AED training. 206 (5) The immunity from civil liability for any personal 207 injury under subsection (3) of this section includes the licensed 208 physician who prescribes the auto-injectable epinephrine, the 209 school district, or any other entity, that legally obtained the 210 auto-injectable epinephrine, and the person who provides the 211 training in the administration of auto-injectable epinephrine. 212 (6) The immunity from civil liability under subsection (2) 213 and subsection (3) of this section does not apply if the personal 214 injury results from the gross negligence or willful or wanton 215 misconduct of the person rendering the emergency care. S. B. No. 2485 15/SS02/R286SG PAGE 9 *SS02/R286SG* ~ OFFICIAL ~ 216 (7) Except in cases of gross negligence or willful 217 misconduct, civil immunity shall apply to any licensed physician 218 or licensed pharmacist who prescribes or makes recommendation to 219 an eligible patient regarding prescription for or treatment with 220 an investigational drug, biological product or device under the 221 provisions of Section 1 of this act, and the State Board of 222 Medical Licensure and/or the State Board of Pharmacy, as the case 223 may be, shall be prohibited from taking any adverse action against 224 the license of such physician or pharmacist based solely on the 225 physician's action under the provisions of Section 1 of this act. 226 227 SECTION 3. This act shall take effect and be in force from and after July 1, 2015. S. B. No. 2485 15/SS02/R286SG PAGE 10 ~ OFFICIAL ~ ST: Investigational drugs; authorize physicians to prescribe to certain eligible terminally ill patients. *SS02/R286SG*
© Copyright 2024